z-logo
open-access-imgOpen Access
Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy
Author(s) -
Murat Sarı,
Adnan Aydıner
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_757_19
Subject(s) - erlotinib , epidermal growth factor receptor , medicine , lung cancer , oncology , gefitinib , erlotinib hydrochloride , cancer research , adenocarcinoma , egfr inhibitors , tyrosine kinase , cancer , receptor
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced NSCLC patients with sensitizing EGFR mutations. There are many complex and rare mutations in the EGFR gene. The efficacy of the first-generation EGFR-TKI (erlotinib) is unknown for tumors harboring rare EGFR mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here